S
Shattuck Labs D
D
STTK
6.77000
USD
-0.16
(-2.31%)
Market Closed
Volume
0
EPS
-1
Div Yield
-
P/E
-10
Market Cap
511,688,698
Title: Shattuck Labs
Sector: Healthcare
Industry: Biotechnology
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325,which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.